Cite

Copy

Tap on and choose 'Add to Home Screen' to create a shortcut app

Tap on and choose 'Install/Install App' to create a shortcut app

On the Horizon for Nonsyndromic Craniosynostosis in Children

This page was last updated on May 9th, 2017

FGFR Pathway

  • Key is first trimester diagnosis risk: The FGFR pathway has been implicated in the formation of craniosynostosis. In vitro and in vivo mouse studies have focused on potential drugs that affect it. Pharmacological agents include tyrosine inhibitors, NOGGIN protein, and anti- TGFβ2 antibody injected or placed locally onto the suture. There is promising information that suggests that sutural fusion may be inhibited (67). However, these drugs must be given in the first trimester of gestation, applied to the suture before closure, and may have detrimental effects on normal metabolic pathways. Genetic studies will continue to elucidate the molecular cause of craniosynostosis and may lead to nonsurgical, noninvasive therapy for this disorder (54).

Bone Engineering

  • Bone substitutes: Studies are beginning to appear about bone generators and scaffolding material in animal models. While not currently applicable to single suture craniosymostosis, they do bear watching (72).

Your donations keep us going

The ISPN Guide is free to use, but we rely on donations to fund our ongoing work and to maintain more than a thousand pages of information created to disseminate the most up-to-date knowledge in the field of paediatric neurosurgery.

By making a donation to The ISPN Guide you are also indirectly helping the many thousands of children around the world whose treatment depends on well-informed surgeons.

Please consider making a donation today.

Use the app

The ISPN Guide can be used as a standalone app, both on mobile devices and desktop computers. It’s quick and easy to use.

Fully featured

Free registration grants you full access to The Guide and host of featured designed to help further your own education.

Stay updated

The ISPN Guide continues to expand both in breadth and depth. Join our mailing list to stay up-to-date with our progress.